<p>Athira Pharma, Inc.（納斯達克股票代碼：ATHA - 獲取免費報告）在六月份看到了空頭頭寸的顯著增長。截至 6 月 15 日，空頭頭寸總計為 1,010,000 股，比 5 月 31 日的 889,500 股增長了 13.5%。基於平均每日交易量為 173,900 股，目前的空頭頭寸比率為 5.8 天。目前，該股的 2.9% 股份被空頭賣空。</p>
<p>獲取 <strong>Athira Pharma</strong> 警報：</p>
<h2>Athira Pharma 交易上漲 0.4%</h2>
<ul>
<li>這些生物技術公司致力於多種神經退行性疾病</li>
</ul>
<p>ATHA 股票週一開盤價為$2.65。該股市值為$1.0157 億，市盈率為-0.87，β值為 2.91。Athira Pharma 的 12 個月最低價為$1.33，最高價為$4.30。該公司的 50 天移動平均價格為$2.37，200 天移動平均價格為$2.72。</p>
<p>Athira Pharma（納斯達克股票代碼：ATHA - 獲取免費報告）上次公佈財報是在 5 月 15 日星期三。公司報告該季度每股虧損 ($0.69)，超過分析師預期的 ($0.80) $0.11。賣方分析師預測，Athira Pharma 今年將發佈-2.79 美元的每股收益。</p>
<h2>內部交易</h2>
<p>在其他 Athira Pharma 新聞中，董事 Kelly A. Romano 於 6 月 24 日星期一以每股$2.42 的平均價格收購了公司的 27,400 股股票。購買後，該董事現在直接持有公司 80,715 股股票，價值約$195,330.30。這筆交易已在美國證券交易委員會（SEC）的法律文件中披露。此外，Kelly A. Romano 董事於 6 月 24 日星期一以每股$2.42 的平均價格購買了 27,400 股 Athira Pharma 股票，總價值為$66,308.00。購買後，該董事現在持有公司 80,715 股股票，價值為$195,330.30。這筆交易已在美國證券交易委員會的文件中披露，可通過此鏈接訪問。此外，Kelly A. Romano 董事於 6 月 21 日星期五以每股$2.26 的平均價格購買了 15,000 股 Athira Pharma 股票，總交易額為$33,900.00。購買完成後，該董事現在直接持有公司 53,315 股股票，價值$120,491.90。有關此次購買的披露可在此處找到。目前，19.80% 的股份由公司內部持有。</p>
<h2>Athira Pharma 的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Jacobs Levy Equity Management Inc.在第一季度將其在 Athira Pharma 的持股增加了 84.1%。Jacobs Levy Equity Management Inc.現在擁有公司 497,475 股股票，價值$1,363,000，較之前增加了 227,278 股。Acadian Asset Management LLC 在第一季度將其在 Athira Pharma 的持倉增加了 281.5%。Acadian Asset Management LLC 現在擁有公司 549,938 股股票，價值$1,505,000，較之前增加了 405,793 股。Mirador Capital Partners LP 在第一季度購入了 Athira Pharma 的新股份，價值約$57,000。Perceptive Advisors LLC 在第四季度將其在 Athira Pharma 的持股增加了 12.6%。Perceptive Advisors LLC 現在擁有公司 5,402,964 股股票，價值$13,129,000，較之前增加了 605,686 股。最後，Forefront Analytics LLC 在第四季度將其在 Athira Pharma 的持股增加了 43.0%。Forefront Analytics LLC 現在擁有公司 29,765 股股票，價值$72,000，較之前增加了 8,955 股。對沖基金和其他機構投資者擁有公司 57.12% 的股份。</p>
<h2>分析師評級變動</h2>
<p>另外，JMP Securities 重申了對 Athira Pharma 股票的&#34;市場表現優異&#34;評級，並在 6 月 20 日星期四的研究報告中給出了$19.00 的目標價。</p>
<p><strong>查看我們對 ATHA 的最新分析</strong></p>
<h2>關於 Athira Pharma（獲取免費報告）</h2>
<p>Athira Pharma, Inc 是一家晚期臨牀階段的生物製藥公司，專注於開發小分子藥物以恢復神經健康並減緩神經退化。其主要產品候選藥物是 Fosgonimeton（ATH-1017），這是一種小分子藥物，旨在調節神經營養肝細胞生長因子（HGF）系統及其受體 MET，用於治療阿爾茨海默病的 LIFT-AD 第 2/3 期和 ACT-AD 第 2 期臨牀試驗，以及用於治療帕金森病痴呆和帶有 Lewy 小體的第 2 期臨牀試驗。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Athira Pharma</li>
<li>金叉股票：模式、示例和圖表</li>
<li>Upwork 股票展望：儘管面臨 Gen-AI 挑戰，數字仍穩健</li>
<li>在購買股票之前如何評估一家公司</li>
<li>瓦爾格林股票暴跌背後的原因：投資者下一步該怎麼做</li>
<li>什麼是 MarketRank™？如何使用</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
</ul>
<p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 年輕億萬富翁為數百萬美國人打開大門（來自 Porter &amp; Company）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0"/></p>
<h2>現在是否值得投資$1,000 在 Athira Pharma？</h2>
<p>在考慮 Athira Pharma 之前，您會想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後等待整個市場的關注... 而 Athira Pharma 並不在這份名單上。</p>
<p>雖然 Athira Pharma 目前在分析師中有一個 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ATHA

LONA

<p>Athira Pharma（納斯達克股票代碼：ATHA）在六月份看到空頭頭寸顯著增加，共計 1,010,000 股，比五月份增長了 13.5%。該股目前的償付天數比率為 5.8，有 2.9% 的股份被賣空。此外，董事 Kelly A. Romano 購入了該公司股票。對沖基金和機構投資者也積極參與了 Athira Pharma 股票的交易</p>

<p>Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,010,000 shares, a growth of 13.5% from the May 31st total of 889,500 shares. Based on an average daily volume of 173,900 shares, the short-interest ratio is currently 5.8 days. Currently, 2.9% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>Athira Pharma, Inc.（納斯達克股票代碼：ATHA - 獲取免費報告）在六月份看到了空頭頭寸的顯著增長。截至 6 月 15 日，空頭頭寸總計為 1,010,000 股，比 5 月 31 日的 889,500 股增長了 13.5%。基於平均每日交易量為 173,900 股，目前的空頭頭寸比率為 5.8 天。目前，該股的 2.9% 股份被空頭賣空。</p>
</div><p>Get <strong>Athira Pharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Athira Pharma</strong> 警報：</p>
</div><h2>Athira Pharma Trading Up 0.4 %</h2>
<ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><h2>Athira Pharma 交易上漲 0.4%</h2>
<ul>
<li>這些生物技術公司致力於多種神經退行性疾病</li>
</ul>
</div><p>ATHA stock opened at $2.65 on Monday. The stock has a market cap of $101.57 million, a PE ratio of -0.87 and a beta of 2.91. Athira Pharma has a 12 month low of $1.33 and a 12 month high of $4.30. The company has a 50-day moving average price of $2.37 and a 200 day moving average price of $2.72.</p>
<div class="lb-trans"><p>ATHA 股票週一開盤價為$2.65。該股市值為$1.0157 億，市盈率為-0.87，β值為 2.91。Athira Pharma 的 12 個月最低價為$1.33，最高價為$4.30。該公司的 50 天移動平均價格為$2.37，200 天移動平均價格為$2.72。</p>
</div><p>Athira Pharma (NASDAQ:ATHA - Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.11. Sell-side analysts forecast that Athira Pharma will post -2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Athira Pharma（納斯達克股票代碼：ATHA - 獲取免費報告）上次公佈財報是在 5 月 15 日星期三。公司報告該季度每股虧損 ($0.69)，超過分析師預期的 ($0.80) $0.11。賣方分析師預測，Athira Pharma 今年將發佈-2.79 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部交易</h2>
</div><p>In other Athira Pharma news, Director Kelly A. Romano acquired 27,400 shares of the company's stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the purchase, the director now directly owns 80,715 shares of the company's stock, valued at approximately $195,330.30. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Athira Pharma news, Director Kelly A. Romano purchased 27,400 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at $195,330.30. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Romano acquired 15,000 shares of Athira Pharma stock in a transaction on Friday, June 21st. The shares were bought at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares of the company's stock, valued at $120,491.90. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Athira Pharma 新聞中，董事 Kelly A. Romano 於 6 月 24 日星期一以每股$2.42 的平均價格收購了公司的 27,400 股股票。購買後，該董事現在直接持有公司 80,715 股股票，價值約$195,330.30。這筆交易已在美國證券交易委員會（SEC）的法律文件中披露。此外，Kelly A. Romano 董事於 6 月 24 日星期一以每股$2.42 的平均價格購買了 27,400 股 Athira Pharma 股票，總價值為$66,308.00。購買後，該董事現在持有公司 80,715 股股票，價值為$195,330.30。這筆交易已在美國證券交易委員會的文件中披露，可通過此鏈接訪問。此外，Kelly A. Romano 董事於 6 月 21 日星期五以每股$2.26 的平均價格購買了 15,000 股 Athira Pharma 股票，總交易額為$33,900.00。購買完成後，該董事現在直接持有公司 53,315 股股票，價值$120,491.90。有關此次購買的披露可在此處找到。目前，19.80% 的股份由公司內部持有。</p>
</div><h2>Institutional Trading of Athira Pharma</h2>
<div class="lb-trans"><h2>Athira Pharma 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its stake in Athira Pharma by 84.1% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company's stock worth $1,363,000 after buying an additional 227,278 shares during the period. Acadian Asset Management LLC increased its position in shares of Athira Pharma by 281.5% during the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company's stock worth $1,505,000 after acquiring an additional 405,793 shares during the period. Mirador Capital Partners LP bought a new stake in shares of Athira Pharma during the first quarter valued at approximately $57,000. Perceptive Advisors LLC boosted its holdings in shares of Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company's stock valued at $13,129,000 after purchasing an additional 605,686 shares during the period. Finally, Forefront Analytics LLC grew its stake in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company's stock worth $72,000 after purchasing an additional 8,955 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了該公司的股票。Jacobs Levy Equity Management Inc.在第一季度將其在 Athira Pharma 的持股增加了 84.1%。Jacobs Levy Equity Management Inc.現在擁有公司 497,475 股股票，價值$1,363,000，較之前增加了 227,278 股。Acadian Asset Management LLC 在第一季度將其在 Athira Pharma 的持倉增加了 281.5%。Acadian Asset Management LLC 現在擁有公司 549,938 股股票，價值$1,505,000，較之前增加了 405,793 股。Mirador Capital Partners LP 在第一季度購入了 Athira Pharma 的新股份，價值約$57,000。Perceptive Advisors LLC 在第四季度將其在 Athira Pharma 的持股增加了 12.6%。Perceptive Advisors LLC 現在擁有公司 5,402,964 股股票，價值$13,129,000，較之前增加了 605,686 股。最後，Forefront Analytics LLC 在第四季度將其在 Athira Pharma 的持股增加了 43.0%。Forefront Analytics LLC 現在擁有公司 29,765 股股票，價值$72,000，較之前增加了 8,955 股。對沖基金和其他機構投資者擁有公司 57.12% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Separately, JMP Securities restated a &#34;market outperform&#34; rating and issued a $19.00 price target on shares of Athira Pharma in a research report on Thursday, June 20th.</p>
<div class="lb-trans"><p>另外，JMP Securities 重申了對 Athira Pharma 股票的&#34;市場表現優異&#34;評級，並在 6 月 20 日星期四的研究報告中給出了$19.00 的目標價。</p>
</div><p><strong>Check Out Our Latest Analysis on ATHA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ATHA 的最新分析</strong></p>
</div><h2>About Athira Pharma (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Athira Pharma（獲取免費報告）</h2>
</div><p>Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Athira Pharma, Inc 是一家晚期臨牀階段的生物製藥公司，專注於開發小分子藥物以恢復神經健康並減緩神經退化。其主要產品候選藥物是 Fosgonimeton（ATH-1017），這是一種小分子藥物，旨在調節神經營養肝細胞生長因子（HGF）系統及其受體 MET，用於治療阿爾茨海默病的 LIFT-AD 第 2/3 期和 ACT-AD 第 2 期臨牀試驗，以及用於治療帕金森病痴呆和帶有 Lewy 小體的第 2 期臨牀試驗。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Athira Pharma</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What is MarketRank™? How to Use it</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Athira Pharma</li>
<li>金叉股票：模式、示例和圖表</li>
<li>Upwork 股票展望：儘管面臨 Gen-AI 挑戰，數字仍穩健</li>
<li>在購買股票之前如何評估一家公司</li>
<li>瓦爾格林股票暴跌背後的原因：投資者下一步該怎麼做</li>
<li>什麼是 MarketRank™？如何使用</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，以向讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Young billionaire opens the door for millions of Americans (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 年輕億萬富翁為數百萬美國人打開大門（來自 Porter &amp; Company）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8594&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Athira Pharma right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Athira Pharma？</h2>
</div><p>Before you consider Athira Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Athira Pharma 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Athira Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票，然後等待整個市場的關注... 而 Athira Pharma 並不在這份名單上。</p>
</div><p>While Athira Pharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Athira Pharma 目前在分析師中有一個 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Athira Pharma 公司（NASDAQ:ATHA）空頭頭寸更新